In order to improve antibody therapy for IBD, Yang and coworkers recently demonstrated a nano-platform to orally deliver TNF-α antibody, infliximab, by using hydrogen bonding supramolecular NPs assembled with tannic acid and 1,2-distearoy-sn-glycero-3-phsphoethanolamine-N-[methoxy(polyethylene glycol)] (DSPE-PEG). This evidence concerns the gene TNF and inflammatory bowel disease.